Friday, November 20, 2026
Late edition · Updated as it breaks
Log inSubmit a story

“All the news worth catching.”

PaparazziPaparazzi
Top storiesBack PageHow to earnLeaderboard
Catcher tip lineCaught a story first? Earn stock tokens →
Sponsored
Premium projects
DEDeFadePAPackedYour project here
PaparazziPaparazzi

All the news worth catching.

Breaking news on tech, crypto, EVs, e-commerce and social the moment it breaks. Written by AI from verified reporting.

SectionsTop storiesRobinhood ChainTech & AIE-commerceWeb3 & CryptoEV & EnergyGlobal & SocialEntertainmentGamingSportsBusiness & marketsHealth & sciencePolitics & world
EarnStart hereSubmit a storyGTA WeekHow to earnLeaderboardContestsCatcher desksTop catchers by reputationAssignmentsLeagueNews bountiesCityMy catchesRewards
MarketsLive statsProof of payoutsWhale watchDeep Scan token checksStock fundHolder perksRobinhood Chain launchesRobinhood Chain projectsList your projectPremium project pagesPartnersThe Chain Weekly
PaparazziPaparazzi InkPaparazzi Ink top writersOpinionLive coverageEvents calendarThe Back PageSuggest a Back Page storyPaparazzi on TelegramHow it worksFAQProof of workAbout usHow we score trustEditorial policyPrivacy policyCorrectionsRelease notesAdvertiseMedia kitNews APIContact
$PAPA contract · Robinhood Chain
© 2026 Paparazzi

Written by AI from verified reporting. Not financial advice.

  • Home
  • Submit
  • Earn
  • Sign in
Top storiesRobinhood ChainTech & AIE-commerceWeb3 & CryptoEV & EnergyGlobal & SocialEntertainmentGamingSportsBusiness & marketsHealth & sciencePolitics & worldWhales
Health & science
Important· 57

Shionogi Snags Biotech Startup in Massive $2 Billion Rare Disease Power Play

Shionogi just closed a massive $2 billion deal to acquire Texas biotech IntraBio! The Japanese pharma giant is folding the company into its structure, taking full control of AQNEURSA, a drug offering life-changing treatment for several rare neurological disorders.

By the Paparazzi desk November 20, 2026 · 5:47 AM · hoodline.com · 0 views
Fact boxTrust 50/100 · Developing
What we verified
  • Original source: hoodline.com.
  • The source published it on Nov 20, 2026 at 5:47 AM.
What we couldn't
  • No second outlet has reported it yet. Treat it as a single-source claim.

Shionogi Inc. officially completed its $2 billion acquisition of Texas-based biotech company IntraBio Inc., making a major splash in the rare disease market. The acquisition finished on November 18, turning IntraBio into a wholly owned subsidiary of the Japanese pharmaceutical giant.

AQNEURSA, the drug at the heart of the deal, is a treatment for devastating rare neurological disorders like Niemann-Pick disease type C. The FDA granted the drug approval in 2024, and it received EU approval in January 2026 for the neurological effects of that specific disease.

Sponsored

The drug's influence keeps growing, having received FDA approval in September 2026 as the sole treatment option for ataxia in adults and children with ataxia-telangiectasia. Shionogi is also currently studying AQNEURSA for CACNA1A neurological disorders in a Phase III trial.

The purchase bolsters Shionogi’s pipeline significantly, bringing programs targeting Fragile X syndrome, Pompe disease, and Jordan's syndrome into their portfolio. Financially, IntraBio posted sales of $68 million in 2025, according to BioPharma Dive.

Shionogi officials are thrilled, with CEO Nathan McCutcheon noting that acquisitions like this help build a strong, sustainable presence in the rare disease space. Patient advocacy groups like the A-T Children's Project have welcomed the deal, hoping Shionogi's resources expand access to the treatment.

This massive purchase follows a prior major move earlier this year when Shionogi secured rights to ALS treatments Radicava ORS and IV Radicava in a $2.5 billion deal in April 2026.

Share

Source: hoodline.com

Written by AI from verified reporting.

More stories

  • Health & science 11:46 UTC · 5 hours ago · finance.yahoo.com · 1 view
    Medtronic's Hugo robot clears FDA for general surgery
  • Health & science 11:31 UTC · 5 hours ago · wired.com · 1 view
    El Niño Pushes California's Coastal Waters Off the Charts, and the Storms Are Following
  • Health & science 11:16 UTC · 6 hours ago · biobuzz.io · 1 view
    FDA approves AstraZeneca's once-weekly Klygefa for generalised myasthenia gravis
  • Health & science 11:16 UTC · 6 hours ago · theguardian.com 2 sources· 1 view
    Pancreatic cancer pill erases tumours in 1 in 12 patients, trial finds
Catcher tip line

Caught a story we missed?

Log in and send it in. If it checks out, it runs with your name on it and you earn stock tokens. The bigger the story, the bigger the reward.

Submit a story
The newsletter

Get the paper in your inbox.

A short digest of the biggest news, plus optional breaking alerts. Free, no account needed.